- Home
- LCTX vs MMD Comparison
LCTX vs MMD Comparison
Compare LCTX & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- MMD
- Stock Information
- Founded
- LCTX 1990
- MMD 2012
- Country
- LCTX United States
- MMD United States
- Employees
- LCTX N/A
- MMD N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- MMD Investment Managers
- Sector
- LCTX Health Care
- MMD Finance
- Exchange
- LCTX Nasdaq
- MMD Nasdaq
- Market Cap
- LCTX 274.0M
- MMD 274.9M
- IPO Year
- LCTX N/A
- MMD N/A
- Fundamental
- Price
- LCTX $1.21
- MMD $14.59
- Analyst Decision
- LCTX Strong Buy
- MMD
- Analyst Count
- LCTX 4
- MMD 0
- Target Price
- LCTX $4.25
- MMD N/A
- AVG Volume (30 Days)
- LCTX 1.5M
- MMD 74.7K
- Earning Date
- LCTX 08-12-2025
- MMD 01-01-0001
- Dividend Yield
- LCTX N/A
- MMD 4.88%
- EPS Growth
- LCTX N/A
- MMD N/A
- EPS
- LCTX N/A
- MMD N/A
- Revenue
- LCTX $10,914,000.00
- MMD N/A
- Revenue This Year
- LCTX N/A
- MMD N/A
- Revenue Next Year
- LCTX $178.80
- MMD N/A
- P/E Ratio
- LCTX N/A
- MMD N/A
- Revenue Growth
- LCTX 76.43
- MMD N/A
- 52 Week Low
- LCTX $0.37
- MMD $14.30
- 52 Week High
- LCTX $1.31
- MMD $17.67
- Technical
- Relative Strength Index (RSI)
- LCTX 59.58
- MMD 50.52
- Support Level
- LCTX $1.15
- MMD $14.48
- Resistance Level
- LCTX $1.31
- MMD $14.62
- Average True Range (ATR)
- LCTX 0.08
- MMD 0.18
- MACD
- LCTX 0.01
- MMD -0.01
- Stochastic Oscillator
- LCTX 70.59
- MMD 32.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.